AC Immune Reports Third Quarter 2018 Financial Results and Corporate Update

Tuesday, November 13, 2018 @ 12:15 pm

Announced important clinical milestones for ACI-24 vaccine in Alzheimer's disease and Down Syndrome
Company record high, period end cash position of approximately CHF 200 million that is expected to extend our cash runway to Q3 2021, excluding potential incoming milestones
Successfully issued 10 million new shares via three offerings to raise gross proceeds of USD 117.5 (CHF 116.3) million

AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced financial results for the three and nine months ended September 30, 2018.

You may also be interested in

Swiss Biotech Report 2024 shows sector performing well in 2023 by continuing to embrace international alliances

Record revenues of CHF 7.3 billion (USD 8.1 billion) – Capital investments increase by more than 50% to CHF 2 billion – CHF 1.4 billion by public companies, CHF 0.6 billion by private companies – Significant licensing and M&A activity in 2023 – VectivBio, T3, Vertex, Santhera – R&D investments of publicly traded biotech companies have decreased in line with global markets, wherea
April 23, 2024

LubioScience and IDT launch gene product for biotech applications

LubioScience, Switzerland’s largest R&D reagent platform, has teamed up with Integrated DNA Technologies (IDT) to launch Rapid Genes, a revolutionary product designed to streamline high-throughput workflows. The genes are shipped in as little as five business days, offering speed and precision that will significantly benefit researchers and biotech companies.
September 13, 2024

Bioversys receives USD 6 million from Guangzhou Sino-Israel Bio-Industry Investment Fund

GIBF2 to invest US$ 6m in BioVersys BV100 Phase 1 study in China expected to start in 1H 2025 in preparation for a global Phase 3 registrational study
September 11, 2024

ABCDX: Heart-type fatty acid binding protein as biomarker for Transient Ischemic Attack

ABCDx, a leader in brain injury diagnostics, is proud to announce the acceptance of the article, "Heart-type fatty acid binding protein as a biomarker in transient ischemic attack," for publication in the prestigious journal, Cardiovascular Translational Research. This pivotal study highlights the innovative use of Heart-type Fatty Acid Binding Protein (H-FABP) as a diagnostic biomarker for Transi
September 9, 2024

Boehringer Ingelheim and CDR-Life advance treatment for Geographic Atrophy

Boehringer Ingelheim and CDR-Life today announce positive results from the Phase I evaluation of BI 771716 (Study Record | ClinicalTrials.gov), an investigational antibody fragment developed to preserve vision in people living with geographic atrophy (GA). BI 771716 met its primary safety endpoint following intravitreal administration of single and multiple doses. Preparation for the Phase II tria
September 5, 2024

HAYA Therapeutics: Collaboration with Eli Lilly to target obesity and related metabolic conditions

HAYA Therapeutics Announces Collaboration with Lilly to Discover Novel Regulatory Genome Targets for Obesity and Related Metabolic Conditions Using Proprietary RNA Platform
September 4, 2024